Genmab | GEN - Fremdkapital

Aktienkurs
1,690.00
Täglich Wechseln
35.00 2.11%
Monatlich
-1.34%
Jährlich
20.80%
Q2 Prognose
1,628.53




Fremdkapital Veränderung Datum
Agios Pharmaceuticals USD 1.06M 0 2022-09
Almirall EUR 324.81M 61.32M 2025-12
Amgen USD 50B 2.43B 2025-12
argenx SE USD 35.57M 3.05M 2025-06
AstraZeneca USD 25.96B 177M 2026-03
Bayer EUR 31.83B 877M 2025-12
BioMarin Pharmaceutical USD 597.18M 513K 2025-12
Demant DKK 18.98B 3.71B 2025-12
Fresenius Medical Care EUR 4.85B 4.49B 2025-12
Galapagos EUR 5.19M 574K 2025-12
Genmab DKK 5.14B 5.01B 2025-12
GlaxoSmithKline GBP 14.01B 696M 2026-03
GN Store Nord DKK 8.9B 9M 2025-12
GRIFOLS EUR 8.47B 624.81M 2025-12
Hikma Pharmaceutical USD 1.49B 692M 2025-12
Insmed USD 540.96M 1.24M 2025-12
Lonza CHF 3.88B 323M 2025-12
Merck EUR 10.73B 277M 2025-12
Novartis USD 29.59B 5.35B 2025-12
Regeneron Pharmaceuticals USD 1.99B 719.7M 2026-03
Roche Holding CHF 27.43B 966M 2025-12
Sanofi EUR 13.84B 1.88B 2026-03
UCB EUR 2.18B 634M 2025-12